These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19695435)

  • 1. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
    Grabenbauer GG; Gerber KD; Ganslandt O; Richter A; Klautke G; Birkmann J; Meyer M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):164-9. PubMed ID: 19695435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
    Gross MW; Altscher R; Brandtner M; Haeusser-Mischlich H; Chiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Clin Neurol Neurosurg; 2005 Apr; 107(3):207-13. PubMed ID: 15823676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy in patients with glioblastoma: is there any benefit?
    Hau P; Baumgart U; Pfeifer K; Bock A; Jauch T; Dietrich J; Fabel K; Grauer O; Wismeth C; Klinkhammer-Schalke M; Allgäuer M; Schuierer G; Koch H; Schlaier J; Ulrich W; Brawanski A; Bogdahn U; Steinbrecher A
    Cancer; 2003 Dec; 98(12):2678-86. PubMed ID: 14669289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
    Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
    BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.
    Chen AM; Chang S; Pouliot J; Sneed PK; Prados MD; Lamborn KR; Malec MK; McDermott MW; Berger MS; Larson DA
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):825-30. PubMed ID: 17512132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
    Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
    J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
    Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.
    Colman H; Berkey BA; Maor MH; Groves MD; Schultz CJ; Vermeulen S; Nelson DF; Mehta MP; Yung WK;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):818-24. PubMed ID: 16887285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
    Kocher M; Eich HT; Semrau R; Güner SA; Müller RP
    Strahlenther Onkol; 2005 Jan; 181(1):20-5. PubMed ID: 15660189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme.
    Mizumoto M; Tsuboi K; Igaki H; Yamamoto T; Takano S; Oshiro Y; Hayashi Y; Hashii H; Kanemoto A; Nakayama H; Sugahara S; Sakurai H; Matsumura A; Tokuuye K
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):98-105. PubMed ID: 19695794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).
    Gross MW; Altscher R; Brandtner M; Häusser-Mischlich H; Kiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Strahlenther Onkol; 2001 Dec; 177(12):656-61. PubMed ID: 11789404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
    Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
    Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme.
    Kong DS; Nam DH; Lee JI; Park K; Kim JH
    J Neurosurg; 2006 Dec; 105 Suppl():139-43. PubMed ID: 18503347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
    Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy.
    Grunnet ML; O'Neill A; Gilbert M; Hellman R
    Clin Neuropathol; 2000; 19(5):230-4. PubMed ID: 11048748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
    Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.